All lobbying filings

THE MCMANUS GROUP

Lobbying for GILEAD SCIENCES, INC. · Client is a biopharmaceutical company that develops medicines in areas of unmet need.

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · California · House · Senate · $60,000.00 income · posted Jan 20, 2026

Official filing document

Bills named in this filing 2

S 832
EPIC Act of 2025
HR 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…

Lobbying activity 2

Health Issues

Issues related to reforming and increasing transparency within the 340B Drug Pricing Program. Issues related to federal funding for HIV prevention.

Medicare/Medicaid

Support for EPIC Act - S. 832, and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Policies related to the Most Favored Nation Drug Pricing Model.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.